.
MergerLinks Header Logo

Announced

Ampersand Capital Partners-backed N2 Biomedical to merge with Precision Coating.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

United States

Acquisition

medical coatings

Private Equity

Private

Majority

Friendly

Single Bidder

Pending

Merger

Biotechnology

Domestic

Synopsis

Edit

Ampersand Capital Partners-backed N2 Biomedical, a provider of nano-engineered surface treatment and coating services, agreed to merge with Precision Coating, a medical coatings service provider. Financial terms were not disclosed. "We are very excited to add N2's technologies and people to Precision Coating. N2 extends our coating platform technologies in ways that enhance our value proposition for customers. This is particularly true in orthopedics, where we can now offer engineered coating solutions across both instruments and implants," Bill Ellerkamp, Precision Coating President.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US